Healthcare

The Ruth Group boasts one of the strongest and most established healthcare focused practices in the investor relations industry. Our designated teams devoted to medical technology, biotechnology/pharmaceuticals and healthcare services allow for an unmatched level of specialization and sector knowledge. Our approach provides our clients with a group of consultants with a deep understanding of industry-specific marketplace, competitive environment, regulatory, reimbursement and clinical matters. Each of our teams is seasoned in articulating to healthcare investors how science, technology and milestones contribute to the growth profile of a clients’ businesses.

The Ruth Group is considered a trusted and reliable source by healthcare-specific investors, investment bankers and top-tier trade and business reporters. Included in our healthcare team are professionals with backgrounds in molecular biology and biochemistry.

Our medical technology team is experienced in working across a broad array of sub-sectors, including orthopedics/spine, cardiology, neurology, diabetes, oncology, respiratory, diagnostics and aesthetics. These consultants are well-versed in the med-tech company life cycle, product milestones and HDE, PMA and 510(k) timelines. In an industry where innovation governs competitive dynamics, med tech companies should demand an IR consultant who is “up the curve.” Our med tech team’s daily monitoring of industry developments and contact with med-tech focused investors and analysts provide clients with an unmatched level of sophistication and real-time industry awareness.

Our biotechnology team combines strong scientific knowledge with consultancy in message development, investor outreach and media relations. Importantly, we are in daily contact with those investors and analysts focused on the space. Recognizing our biotechnology clients consistent need for capital, we focus on tailoring proactive investor relations programs that highlight clinical milestones, scientific differentiators, and news flow. To maximize exposure and investor interest, we offer an integrated approach combining investor programs, with a strategy for milestone visibility, and exposure in key trade and business media outlets. Our media professionals maintain strong relationships with biotechnology trades and the business media that cover the biotechnology area.